– EC authorizes a low-dose tablet for HIV treatment in virologically suppressed children at least two years of age and weighing at least 14 kg, helping to address a critical unmet need –
– Biktarvy provides an effective therapy choice for a diverse range of people living with HIV, including children with limited treatment options –
Read the full press release here.
Source : Gilead Sciences, Inc.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.